Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CTMX stock hub

CytomX Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CTMXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

866.4M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CTMX

In the news

Latest news · CTMX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-34.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-21.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CTMX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

209

Groups with data

Currency

USD

Showing 209 of 209 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001501989
Company name	CytomX Therapeutics, Inc.
Country	United States
Country code	US
Cusip	23284F105
Employees	69
Employees Change	-52%
Employees Change Percent	-42.98
Enterprise value	$522.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-10-08
Isin	US23284F1057
Last refreshed	2026-05-10
Market cap	$866.4M
Market cap category	Small-Cap
Price	$3.98
Price currency	USD
Rev Per Employee	515,101.45x
Sector	Healthcare
Sic	2834
Symbol	CTMX
Website	https://www.cytomx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-7.17%
EV Sales Forward	23.1x
EV/Sales	14.7x
FCF yield	-9.26%
P/B ratio	2.71x
P/S ratio	24.38x
PS Forward	38.3x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-174.04%
EBITDA Margin	-170.54%
Gross margin	100%
Gross Profit	$35.5M
Gross Profit Growth	-75.91%
Gross Profit Growth Q	-79.85%
Gross Profit Growth3 Y	-19.3%
Gross Profit Growth5 Y	-11.84%
Net Income	$-62.1M
Net Income Growth Years	0%
Pretax Margin	-165.74%
Profit Margin	-166.4%
Profit Per Employee	$-900,623
ROA	-16.89
Roa5y	-8.27
ROCE	-19.01
ROE	-34.29
ROIC	-21.72

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-10.53%
Cagr1y	314.77%
Cagr3y	32.78%
Cagr5y	-14.18%
EPS Growth Years	0
Revenue Growth	-75.91x
Revenue Growth Q	-79.85x
Revenue Growth Years	0x
Revenue Growth3 Y	-19.3x
Revenue Growth5 Y	-11.84x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.16
Assets	$359.4M
Cash	$346.7M
Current Assets	$353.1M
Current Liabilities	$34M
Debt	$2.9M
Debt Equity	$0.01
Equity	$319.9M
Liabilities	$39.4M
Long Term Assets	$6.3M
Long Term Liabilities	$5.4M
Net Cash	$343.9M
Net Cash By Market Cap	$39.69
Net Cash Growth	379.32%
Net Debt Equity	$-1.07
Tangible Book Value	$318.6M
Tangible Book Value Per Share	$1.46
WACC	16.14

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.38
Net Working Capital	$-24.8M
Quick ratio	10.21
Working Capital	$319.1M
Working Capital Turnover	$0.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-86.87%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-67.13%
1Y total return	314.37%
200-day SMA	3.88
3Y total return	134.12%
50-day SMA	4.59
50-day SMA vs 200-day SMA	50over200
5Y total return	-53.45%
All Time High	35
All Time High Change	-88.63%
All Time High Date	2018-03-08
All Time Low	0.4
All Time Low Change	895%
All Time Low Date	2025-04-07
ATR	0.3
Beta	2.17
Beta1y	3.64
Beta2y	2.42
Ch YTD	-6.57
High	4.23
High52	8.21
High52 Date	2026-03-16
High52ch	-51.52%
Low	3.86
Low52	0.91
Low52 Date	2025-05-09
Low52ch	338.23%
Ma50ch	-13.25%
Premarket Change Percent	1.75
Premarket Price	$4.07
Premarket Volume	25,488
Price vs 200-day SMA	2.52%
RSI	37.85
RSI Monthly	57.82
RSI Weekly	44.99
Sharpe ratio	1.43x
Sortino ratio	3.92
Total Return	-86.87%
Tr YTD	-6.57
Tr1m	-7.44%
Tr1w	-4.78%
Tr3m	-29.81%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	5
Analyst Price Target Top	$15.2
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.12
Earnings Revenue Estimate	4,444,304x
Earnings Revenue Estimate Growth	-91.27x
Operating Income	$-61.9M
Operating margin	-174
Price target	$12.1
Price Target Change	$204
Price Target Change Top	$282

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	189,455,819%
Float Percent	87.03%
Shares Insiders	0.52%
Shares Institutions	63.57%
Shares Out	217,693,878
Shares Qo Q	4.47%
Shares Yo Y	86.87%
Short Float	14.52%
Short Ratio	2.05
Short Shares	12.64

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-89.2M
Average Volume	3,780,434.55x
Bv Per Share	1.47
CAPEX	$-101,000
Ch10y	-67.13
Ch1m	-7.44
Ch1w	-4.78
Ch1y	314.4
Ch3m	-29.81
Ch3y	134.1
Ch5y	-53.45
Ch6m	9.95
Change	-0.5%
Change From Open	-1.49
Close	4
Days Gap	1
Depreciation Amortization	1,242,000
Dollar Volume	20,129,076.9
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-61.9M
EBITDA	$-60.6M
EPS	$-0.39
F Score	1
FCF	$-80.2M
FCF EV Yield	-15.35x
FCF Per Share	$-0.37
Financing CF	344,933,000
Fiscal Year End	December
Founded	2,008
Goodwill	949,000
Income Tax	$235,000
Investing CF	-283,117,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-16
Ma150	4.43
Ma150ch	-10.14%
Ma20	4.38
Ma20ch	-9.07%
Net CF	-18,277,000
Next Earnings Date	2026-08-06
Open	4.04
Optionable	Yes
Position In Range	33.33
Ppne	3,354,000
Pre Close	4
Price Date	2026-05-08
Ptbv Ratio	2.72
Relative Volume	1.34x
Revenue	35,542,000x
SBC By Revenue	25.32x
Share Based Comp	9,000,000
Tax By Revenue	0.66x
Tr6m	9.95%
Us State	California
Volume	5,057,557

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CTMX pay a dividend?

Capital-return profile for this ticker.

Performance

CTMX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CTMX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+63.6%

Float: +87.0% of shares outstanding

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CTMX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

37.8

Neutral momentum band

Price vs 200-day MA

+2.5%

50/200-day relationship not available

Beta (5Y)

2.17

More volatile than the market

Sharpe ratio

1.43

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CTMX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CTMX stock rating?

CytomX Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CTMX analysis?

The full report lives at /stocks/CTMX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CTMX?

The latest report frames CTMX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CTMX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.